Patents Examined by Karen A. Canella
  • Patent number: 11957732
    Abstract: The present invention discloses compositions and methods for selectively delivering apoptosis inducing agents to the tumor prior to conventional therapeutic treatment protocol. Specifically, the present invention relates to an ensemble (or ‘AAAPT bioconjugate’) comprising an apoptogen (A) and a tumor targeting group (T), wherein the apoptogen is either connected directly to the targeting group or optionally attached through an intervening linker (L). The apoptogen may be a small or large molecule that activates apoptosis pathway and causes cell death. The targeting vector may be a small or large molecule that delivers the apoptogen selectively to the tumors. The linker may comprise simple alkylene chain or may contain functional groups that are capable of being cleaved by enzymatic process.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: April 16, 2024
    Inventor: Raghoottama Pandurangi
  • Patent number: 11951166
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 9, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • Patent number: 11952402
    Abstract: A recombinant protein includes a TRAIL domain and an IgG binding domain IgBD. In the recombinant protein, IgBD can be fused at the N-terminus or C-terminus of the TRAIL domain. The anti-tumor effect of the recombinant protein after binding to endogenous or exogenous IgG is significantly stronger than that of TRAIL, and can be used in the treatment of cell proliferative diseases with high expression of death receptors.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: April 9, 2024
    Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    Inventors: Xiaofeng Lu, Hao Yang, Ze Tao, Jingqiu Cheng
  • Patent number: 11944673
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: April 2, 2024
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Patent number: 11938164
    Abstract: The technology described herein is directed to methods of treating and diagnosing cancer, e.g, by measuring the expression of certain genes in exosomes.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: March 26, 2024
    Inventors: Gerald V. Denis, Louis C. Gerstenfeld, Naser Jafari, Tova Meshulam
  • Patent number: 11938175
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: March 26, 2024
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Patent number: 11903997
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 20, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Patent number: 11904000
    Abstract: The present invention provides compositions and methods to enhance cutaneous wound healing in subjects afflicted with, or at risk for, a pulmonary infection and/or a pulmonary injury. More specifically, the embodiments of the present invention relate to using fibrin carrier as a vehicle to topically deliver one or more chemokine onto a cutaneous wound so as to accelerate wound healing.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: February 20, 2024
    Assignee: BROWN UNIVERSITY
    Inventors: Amanda M. Jamieson, Meredith Crane, Yun Xu
  • Patent number: 11872282
    Abstract: Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 16, 2024
    Assignee: Amgen Inc.
    Inventors: Bruce Allen Bach, Florian Vogl
  • Patent number: 11873336
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 16, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • Patent number: 11873281
    Abstract: A conjugate of a potent cytotoxic agent with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 16, 2024
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventors: R. Yongxin Zhao, Yue Zhang, Yourang Ma
  • Patent number: 11865178
    Abstract: Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 9, 2024
    Assignee: North Carolina State University
    Inventors: Zhen Gu, Yanqi Ye
  • Patent number: 11865149
    Abstract: This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (e.g., one or more replicating oncolytic viruses) to treat cancer in a mammal (e.g., a human) identified as having a cancer likely to respond to oncolytic virotherapy are provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 9, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Kah-Whye Peng, Stephen James Russell, Mitesh J. Borad, Yumei Zhou, Amber C. Miller
  • Patent number: 11866481
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 9, 2024
    Assignee: National Research Council of Canada
    Inventors: Anne E. G. Lenferink, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
  • Patent number: 11865116
    Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 9, 2024
    Assignee: COTHERA BIOSCIENCE, INC.
    Inventors: Thomas M. Estok, Eckard Weber, Tracy Lee Lawhon
  • Patent number: 11858998
    Abstract: The present invention provides methods for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. The subject invention provides biomarkers and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. The subject invention also provides therapeutic targets in cancer for developing anti-cancer therapies.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: January 2, 2024
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Charles J. Dimitroff, Asmi Chakraborty
  • Patent number: 11857637
    Abstract: The present disclosure provides anti-CD25 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: January 2, 2024
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: David Rabuka, Penelope M. Drake
  • Patent number: 11851498
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: December 26, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, BioMed Valley Discoveries, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Patent number: 11850284
    Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: December 26, 2023
    Assignee: Yale University
    Inventors: Elias Quijano, Peter Glazer
  • Patent number: 11845798
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: December 19, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava